The Hemotransmissive Infections Testing Market is becoming an increasingly important component of modern blood-safety and infectious-disease management programs. Market revenue is expected to increase from USD 2.8 billion in 2025 to USD 8.3 billion by 2035 at an 11.6% CAGR, driven by demand for accurate testing, laboratory modernization, and stronger infection-control practices. 

Advances in molecular diagnostics are changing the testing landscape. HBV DNA, HCV RNA, and HIV RNA assays provide molecular approaches for pathogen detection, while automation and high-throughput platforms can help laboratories improve workflow capacity and consistency. 

The hepatitis B testing segment represents a major portion of market demand, while hepatitis C and HIV provide additional application areas. Routine blood screening, clinical diagnosis, treatment monitoring, and public-health programs all contribute to the need for dependable hemotransmissive infection testing. 

Hospitals are the largest end users, with a projected 50% revenue share in 2025, reflecting their extensive testing requirements and blood-safety responsibilities. North America, Asia Pacific, and Europe remain important markets, with developing healthcare systems creating additional opportunities for diagnostic expansion. 

Looking ahead, the industry may increasingly adopt integrated molecular testing, automated sample handling, and software-supported laboratory management. Greater use of multi-pathogen panels and public-health screening initiatives could help expand testing coverage while improving the efficiency of infectious-disease diagnostic workflows. 